FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to the chemical-pharmaceutical industry and is a therapeutic agent for inducing apoptosis of malignant tumour cells and vascular endothelial cells in the tissue(s) of a malignant tumour, as well as an agent for treating benign tumour(s) that can undergo malignant degeneration, where the benign tumour is adenoma of the mammary gland, pituitary adenoma, meningioma, goiter, neurinoma, leiomyoma. Said therapeutic agents contain at least one leukotriene inhibitor selected from the group of compounds consisting of montelukast, zafirlukast and pranlukast; pharmaceutically acceptable salts of said compounds and pharmaceutically acceptable solvates of said compounds and said salts. Invention also includes a therapeutic agent for treating benign tumour(s) which can undergo malignant degeneration, which contains at least one leukotriene inhibitor selected from the group consisting of montelukast and zafirlukast.
EFFECT: inventions reduce side effects in the treatment of malignant and benign tumours.
5 cl, 24 dwg, 1 tbl, 5 ex
